Therapeutic uses of compounds which selectively modulate the CB2 receptor

US8362039B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Alessandra Bartolozzi · Norwalk, US
• Angela Berry · Gaylordsville, US
• Eugene Richard Hickey · Danbury, US
• Markus Ostermeier · Biberach an der Riß, DE
• Doris Riether · Biberach an der Riß, DE
• Achim Sauer · Ravensburg, DE
• David Thomson · Ridgefield, US
• Lifen Wu · New Milford, US
• Renee M. Zindell · New Milford, US
• Patricia Amouzegh · Abingdon, GB
• Nigel James Blumire · Biggenden, AU
• Stephen Peter East · Wallingford, GB
• Monika Ermann · Wantage, GB
• Someina Khor · Abingdon, GB
• Innocent Mushi · Felton, GB

Key dates

• Filing date: Aug 25, 2011
• Grant date: Jan 29, 2013
• Expiry date: Aug 25, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of formula (I)are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.